NFKB1 and plasma cell myeloma: However, the lessons learnt from clinical trials of proteasome (and hence also canonical NF-κB pathway) inhibitors against multiple myeloma dictate that therapeutic interventions into the NF-κB pathway are also associated with significant toxicity, since the pathway acts simultaneously in epithelial and immune cells in opposing fashions [67,68].